How we ranked them
Every programme was scored against ONDA’s published review methodology: six weighted criteria, with insights and analysis quality carrying the most weight because that is the category’s real differentiator. Eight of the ten programmes ship the same two underlying sensors — so sensor accuracy alone does not separate them.
All ten programmes were assessed from manufacturer documentation, the published Dexcom G7 and Abbott Libre 3 validation literature, and independent 2026 reviews rather than hands-on testing, so treat the scores as an evidence-based starting point.
The short version
The market is hardware-converged and software-divergent. Two sensors carry the entire non-diabetic CGM category in 2026: Abbott Libre 3 (Lingo, Ultrahuman M1, Veri, Hello Inside, Zoe, Supersapiens) and Dexcom G7 (Levels, Stelo, Nutrisense, Signos). The wrappers are what you are actually buying.
Two clean breakpoints in the price ladder:
Premium coaching tier ($140–$310/month): Levels, Nutrisense, Signos. Deepest insights, best app design, most expensive. Right pick if CGM is a serious tool, not an experiment.
OTC value tier ($22–$100/month): Lingo, Stelo. No prescription, no subscription required. Same underlying sensors, simpler apps. Right pick if you want to find out whether CGM changes anything for you before committing.
Around those two breakpoints the rest of the field carves out specific use cases — Zoe for multi-biomarker personalisation, Ultrahuman M1 for ring-ecosystem integration, Veri and Hello Inside for EU users, Supersapiens for endurance athletes. The category is small enough that the ten programmes here are effectively the universe; the right answer is which use case fits you.